Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer

18 Feb 2022

Abstract excerpt

We aim to elucidate the prognostic value of PIK3CA mutations and copy number (CN) gain (PIK3CA-mut/gain) in hormone receptor-positive and HER2-negative (HR + /HER2-) breast cancer (BC). We analyzed primary HR + /HER2- BC from three publicly available datasets comprising over 2000 samples and assessed the associations with tumoral and clinical characteristics and outcome. Clinical benefit (CB) in alpelisib-treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Chronic Lymphocytic Leukemia Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35181669
DOI: 10.1038/s41523-022-00382-5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancerPMID 35181669Read ↗

Comparative genomic analysis of PIK3R1-mutated and wild-type breast cancers.Semantic proximity Read ↗

Analysis of PIK3CA Mutations with Clinicopathological Features and Prognosis in Breast cancer patients with Undergoing Neoadjuvant TherapySemantic proximity Read ↗

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.Semantic proximity Read ↗

Analysis of PIK3CA mutations in the primary and recurrent tumors of hormone receptor positive/human epidermal growth factor receptor 2 negative breast cancer.Semantic proximity Read ↗

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification.Semantic proximity Read ↗

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial.Semantic proximity Read ↗

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.Semantic proximity Read ↗

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeSemantic proximity Read ↗

"Beyond HER2 overexpression: somatic alterations in HER2 and PI3K genes in HER2-high and HER2-low/TNBC breast cancer.Semantic proximity Read ↗

Frequency and spectrum of PIK3CA somatic mutations in breast cancer.Semantic proximity Read ↗

Survival analysis of patients with early breast cancer associated with PIK3CA mutationSemantic proximity Read ↗

Analytical Performance of Next-Generation Sequencing and RT-PCR on Formalin-Fixed Paraffin-Embedded Tumor Tissues for PIK3CA Testing in HR+/HER2− Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.